A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
By A. du Bois, H. Lück, W. Meier, H. Adams, V. Möbus, S. Costa, T. Bauknecht, B. Richter, M. Warm, W. Schröder and 7 more. Journal of the National Cancer Institute, 2003
1,103 citations recorded by the source corpus.
Subfields: Oncology, Reproductive Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/a3e1d7cbf0ee37746dcc0b1e02353ec1eda54bc9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Reproductive Medicine
In Surgery
Citations in the corpus
- Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features (2012, background): “Microscopically, HGSCs show papillary and solid growth with slit-like glandular lumens.”
- Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies (2008, background): “The dismal response rate of clear cell carcinomas (15%) contrasts sharply with that of high-grade serous (80%), resulting in a lower 5-y survival for clear cell compared with high-grade serous carcinoma in patients with advanced stage tumors (20% versus 30%) [7,8].”